To investigate the effects of liraglutide combined with short-term intensive insulin therapy on fasting glucose, insulin resistance index(HOMA-IR)and inflammatory response indexes in patients with type 2 diabetes mellitus and obesity.

A retrospective study was performed on 198 cases of patients with type 2 diabetes mellitus combined with obesity who were admitted from February 2017 to March 2019.There were 106 male and 92 female, aged(53.49±7.09)years old, ranging from 36 to 69 years old.Patients were randomly divided into the single treatment group and the combination group, with 99 cases in each group.Single treatment group of patients were given short-term insulin intensive therapy, the combined treatment group of patients were given the liraglutide combined with short-term insulin intensive treatment.Two groups of patients were compared before and after treatment of blood glucose related index[fasting blood glucose, glycosylated hemoglobin(HbA1c), 2 hours postprandial blood glucose(2 hPBG)], homeostasis model assessment-β(HOMA-β), HOMA-IR, inflammatory response index[triglyceride, total cholesterol, low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C)].

After treatment, FBG[(6.87±0.72)mmol/L], HbAlc[(7.06±0.82)%], and 2hPBG[(7.59±0.85)mmol/L]were lower in the combination group than in the single treatment group[(7.37±0.81)mmol/L, (7.69±0.74)%, and(8.95±0.93)mmol/L]. HOMA-β(85.32±18.62)in the combination group was higher than(63.19±12.37)in the single treatment group, HOMA-IR(2.97±0.22)in the combination group was lower than(4.32±0.37)of the single treatment group.Adiponectin levels[(1.76±0.16)μg/L]in the combination group were higher than[(1.38±0.14)μg/L]in the single treatment group.IL-6[(9.34±0.95)ng/L]and TNF-α level[(29.89±4.32)ng/L]in the combination group were lower than[(12.27±1.33)ng/L and[37.18±4.87)ng/L]in the single treatment group.The levels of triglycerides[(0.68±0.09)mmol/L], total cholesterol[(4.48±0.79)mmol/L], LDL-C[(2.35±0.16)mmol/L]in the combination group were lower than[(1.44±0.17)mmol/L, [6.08±0.76)mmol/L, [3.06±0.15)mmol/L]in the single treatment group, and HDL-C[(1.72±0.14)mmol/L]in the combination group was higher than[(1.32±0.12)mmol/L]in the single treatment group, and the differences were statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).

Liraglutide combined with short-term insulin intensive treatment of type 2 diabetes mellitus with obesity can effectively control blood glucose, reduce insulin resistance and inflammatory response, which is worthy of clinical promotion.

Type 2 diabetes mellitus; Obesity; Liraglutide; Insulin